Top 25 Companies Global Plasma-Derived Protein Therapeutics Market in (2025-2033)

The Global Plasma-Derived Protein Therapeutics Market is valued at USD 34.3 Billion in 2025 and is projected to reach USD 57.7 Billion by 2033, growing at a CAGR of 6.7%. This market encompasses products derived from human plasma, vital for treating a range of diseases, including primary immunodeficiencies, coagulation disorders, and various autoimmune conditions. The increasing prevalence of these disorders, alongside advancements in therapeutic technologies, significantly drives market growth.

The demand for plasma-derived therapies continues to rise due to their effectiveness in managing chronic conditions and supporting patients' quality of life. Heightened awareness and improved diagnosis rates contribute to the expanding market. The landscape includes various product segments, with immunoglobulins and albumin leading the way.

Global Plasma-Derived Protein Therapeutics Market Size, Data, & Statistics

The Global Plasma-Derived Protein Therapeutics Market was valued at USD 26.8 Billion in 2021, indicating a steady growth trajectory. In 2022, the market increased to USD 28.4 Billion, showcasing continued demand for plasma-derived products. By 2023, the market reached USD 30.4 Billion, reflecting the expanding application of these therapies.

Forecasts predict the market will grow to USD 32.1 Billion in 2024 and achieve USD 34.3 Billion by 2025. The market is expected to continue its growth, reaching USD 36.7 Billion in 2026. By 2033, the market is set to reach USD 57.7 Billion, highlighting a significant upward trend.

The compound annual growth rate (CAGR) from 2025 to 2033 is projected at 6.7%, indicating significant growth in the sector. This figure highlights the increasing adoption of plasma-derived therapies across various medical conditions.

Regionally, North America represents the largest share at 38.2%, followed by Europe at 28.7%. The Asia Pacific region accounts for 23.5%, while South America and the Middle East and Africa contribute 5.2% and 4.3%, respectively.

Top 10 Trends in the Global Plasma-Derived Protein Therapeutics Market

Increased demand for immunoglobulin therapies

The growing prevalence of immune-related disorders drives demand for immunoglobulin therapies. These products are essential in managing conditions such as primary immunodeficiencies and autoimmune diseases.

Advancements in collection technologies

Improvements in plasma collection technologies enhance efficiency and safety. This progress leads to increased availability of high-quality plasma for therapeutic use, benefiting manufacturers and patients.

Expansion of product portfolios

Companies in the market are expanding their product portfolios to include innovative therapies. This diversification allows firms to cater to a broader range of medical conditions and patient needs.

Focus on personalized medicine

The trend toward personalized medicine influences the development of targeted therapies. Companies are exploring ways to tailor treatments to individual patient profiles, improving outcomes and satisfaction.

Growing investment in research and development

Increased investment in research and development enhances the innovation pipeline. Companies strive to discover new therapies that leverage the unique properties of plasma-derived products.

Regulatory advancements

Streamlined regulatory processes facilitate quicker approvals for new therapies. This trend encourages companies to bring innovative products to market faster, meeting urgent patient needs.

Collaboration with academic institutions

Partnerships with academic institutions drive innovation and knowledge exchange. These collaborations focus on developing new products and improving existing therapies through cutting-edge research.

Rising patient advocacy

Increased advocacy from patient groups influences market dynamics. These organizations raise awareness about plasma-derived therapies, promoting their benefits and driving demand among healthcare providers.

Globalization of supply chains

The globalization of supply chains allows companies to source plasma from diverse regions. This strategy ensures a steady supply of raw materials and enhances production capabilities.

Heightened focus on patient education

Improved patient education initiatives enable individuals to make informed decisions about their treatment options. Education efforts enhance understanding of plasma-derived therapies and their benefits.

Top 25 Companies in the Global Plasma-Derived Protein Therapeutics Market

1. CSL Behring

Headquarters: King of Prussia, USA · Founded: 1904. CSL Behring specializes in developing and delivering innovative therapies for people with serious and rare diseases. It offers a range of plasma-derived products including immunoglobulins and coagulation factors, contributing to the treatment of hemophilia and other bleeding disorders. The company emphasizes high-quality standards and patient-centered approaches in its operations.

2. Takeda Pharmaceutical Company Limited

Headquarters: Tokyo, Japan · Founded: 1781. Takeda is a global biopharmaceutical leader committed to bringing better health to people worldwide. Its plasma-derived therapeutics focus on immunology and hematology, addressing serious health challenges. The company invests heavily in research and development, aiming to innovate and expand its therapeutic offerings.

3. Grifols, S.A.

Headquarters: Barcelona, Spain · Founded: 1909. Grifols is dedicated to improving the health and well-being of patients worldwide through the development of plasma-derived therapies. The company has a comprehensive portfolio of products, including immunoglobulins and albumin, used in critical care and chronic conditions. Grifols prioritizes sustainability and innovation in its production processes.

4. Octapharma AG

Headquarters: Lachen, Switzerland · Founded: 1983. Octapharma specializes in the development of human protein therapies derived from human plasma and human cell lines. With a focus on high-quality production, the company manufactures a variety of therapies, particularly in immunology and hematology, addressing various medical needs.

5. Kedrion S.p.A.

Headquarters: Castelvecchio Pascoli, Italy · Founded: 1966. Kedrion is a global leader in the production of plasma-derived therapies. The company is committed to ensuring the availability of its products for patients suffering from serious medical conditions, focusing on safety and quality in its operations.

6. LFB Group

Headquarters: Les Ulis, France · Founded: 1994. LFB Group is a biopharmaceutical company specializing in the production of human blood-derived products. It develops a wide range of therapies for immunology, hemostasis, and critical care, aiming to meet the needs of patients with rare diseases.

7. Prothya Biosolutions B.V.

Headquarters: Amsterdam, Netherlands · Founded: 2020. Prothya focuses on providing high-quality plasma-derived therapies to improve patient lives. The company emphasizes ethical sourcing and patient safety, ensuring that its products meet rigorous international standards.

8. Beijing Tiantan Biological Products Co., Ltd.

Headquarters: Beijing, China. Beijing Tiantan Biological Products is a key player in the Chinese plasma-derived products market. The company specializes in producing immunoglobulins and other blood products, contributing to the treatment of various conditions.

9. Hualan Biological Engineering Inc.

Headquarters: Henan, China. Hualan Biological Engineering specializes in the research, development, and production of biological products, particularly plasma-derived therapies. The company's focus on quality and technological advancement helps address healthcare challenges.

10. Shanghai RAAS Blood Products Co., Ltd.

Headquarters: Shanghai, China. Shanghai RAAS is dedicated to producing plasma-derived products to support patients with serious conditions. The company emphasizes innovation and quality in its manufacturing processes.

11. GC Biopharma Corp.

Headquarters: Yongin, South Korea. GC Biopharma develops and manufactures a range of plasma-derived therapies, focusing on immunology and critical care. The company's commitment to research and innovation drives its development of new treatment options.

12. SK Plasma Co., Ltd.

Headquarters: Seoul, South Korea. SK Plasma is involved in the production of plasma-derived therapies, contributing to the treatment of various medical conditions. The company prioritizes quality and patient safety in its operations.

13. Japan Blood Products Organization

Headquarters: Tokyo, Japan. This organization plays a vital role in the collection and supply of blood and plasma-derived products in Japan. It ensures the availability of safe and effective therapies for patients in need.

14. ADMA Biologics, Inc.

Headquarters: Ramsey, USA · Founded: 2004. ADMA Biologics focuses on developing and marketing specialty plasma-derived products, particularly for the treatment of immunodeficiencies. The company aims to improve patient outcomes and quality of life through its targeted therapies.

15. Kamada Ltd.

Headquarters: Ness Ziona, Israel · Founded: 1990. Kamada specializes in the development and manufacture of plasma-derived protein therapeutics, addressing various medical conditions. The company emphasizes innovation and patient-centered approaches in its product development.

16. KM Biologics Co., Ltd.

Headquarters: Kumamoto, Japan. KM Biologics focuses on the development of plasma-derived therapies and vaccines. The company's commitment to quality and safety ensures that its products meet the needs of patients.

17. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Headquarters: Chengdu, China. Sichuan Yuanda Shuyang specializes in producing plasma-derived products for therapeutic use. The company is dedicated to ensuring high-quality standards in its production processes.

18. China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Headquarters: Beijing, China. This organization focuses on the production of plasma-derived therapies, contributing to the healthcare landscape in China. Its commitment to quality and patient care is central to its operations.

19. Shenzhen Weiguang Biological Products Co., Ltd.

Headquarters: Shenzhen, China. Weiguang Biological specializes in the research and development of plasma-derived products. The company aims to provide effective therapies for patients with various health conditions.

20. Biopharma Plasma LLC

Headquarters: Minneapolis, USA. Biopharma Plasma focuses on the collection and supply of high-quality plasma for therapeutic use. The company emphasizes safety and efficiency in its operations.

21. Reliance Life Sciences Pvt. Ltd.

Headquarters: Mumbai, India. Reliance Life Sciences is involved in the development of plasma-derived therapies aimed at addressing critical health needs. The company's commitment to research and innovation drives its product development.

22. PlasmaGen BioSciences Pvt. Ltd.

Headquarters: Bangalore, India. PlasmaGen is focused on developing plasma-derived therapies to improve patient outcomes in various health conditions. Its innovative approach centers around patient needs and safety.

23. Virchow Biotech Pvt. Ltd.

Headquarters: Hyderabad, India. Virchow Biotech specializes in the production of plasma-derived products, emphasizing quality and innovation in its offerings. The company's focus on patient care is integral to its mission.

24. Emergent BioSolutions Inc.

Headquarters: Gaithersburg, USA · Founded: 1998. Emergent BioSolutions specializes in developing and manufacturing medical countermeasures, including plasma-derived therapies. The company is dedicated to ensuring public health through innovative solutions.

25. Empresa Brasileira de Hemoderivados e Biotecnologia (Hemobrás)

Headquarters: Pernambuco, Brazil. Hemobrás focuses on the production of plasma-derived products to support healthcare needs in Brazil. The company emphasizes quality and safety in its manufacturing processes.

Conclusion

The Global Plasma-Derived Protein Therapeutics Market is set for significant growth, with the demand for these products rising across multiple regions. This growth is driven by advancements in therapeutic applications and an increasing prevalence of related disorders. The 25 companies highlighted reflect a diverse set of players dedicated to innovating and improving patient outcomes.

For stakeholders in the Plasma-Derived Protein Therapeutics companies landscape, understanding the key players and their offerings provides valuable insights into market dynamics. Engaging with these companies offers opportunities to enhance therapeutic options and address pressing health challenges.